Skip to main content

Can Triumeq be used for PrEP?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Dec 23, 2024.

Official Answer by Drugs.com

Key Points

How is Triumeq used in HIV treatment?

Triumeq, from ViiV Health Care, contains three medicines in one oral tablet: dolutegravir, an integrase strand transfer inhibitor, and two nucleoside reverse transcriptase inhibitors - abacavir and lamivudine.

Triumeq can be used in both adults and children who weigh at least 40 kg (88 pounds) to treat HIV-1 infection. The recommended dose of Triumeq is one tablet once a day with or without food. It’s best to take it at the same time each day, whether you take it in the day or at night.

For many people, Triumeq can be used as the only tablet they will need to take each day for HIV-1 treatment. This treatment can help you reach and maintain an undetectable level of virus in your blood, although individual results may vary. Undetectable means that you have less than 50 copies of HIV-1 RNA in a milliliter (mL) of blood.

However, if you have resistance to any of the three drugs found in Triumeq (dolutegravir, abacavir and lamivudine), it should be used in combination with other HIV medications.

You should not use Triumeq if you have a type of gene variation called the HLA-B*5701 allele.

Take Triumeq at least 2 hours before or 6 hours after you take any medicines that contain aluminum, magnesium, or buffered medicines such as antacids and laxatives.

Iron or calcium supplements can also lead to a drug interaction with Triumeq.

Do not take Triumeq if you take dofetilide (Tikosyn), a medicine used in people with certain heart rhythm disorders (known as arrhythmias). Also, do not take Triumeq with dalfampridine (Ampyra). Taking Triumeq with these drugs can cause serious side effects that may be serious or life-threatening. Do not stop using any medications, including Triumeq, without first talking to your doctor. If you are not sure if you are taking these medications, ask your doctor or pharmacist.

If you have heart disease, kidney or liver disease be sure to tell your doctor. Also, let your doctor know if you are pregnant or plan to become pregnant. This medication could harm an unborn baby.

How well does Triumeq work to treat HIV?

In the SINGLE clinical trial of Triumeq, 833 adults with HIV-1 who had never used HIV-1 treatment before were evaluated (see Table 1). Triumeq was compared to Atripla (efavirenz, emtricitabine, and tenofovir), another medicine used to treat HIV-1 infection.

Overall, more patients were found to reach undetectable levels of HIV-1 RNA at about three years compared to Atripla. The difference was mainly due to more patients on Atripla stopping their medicine because of side effects than patients on Triumeq.

Table 1. SINGLE Study: Triumeq Compared to Atripla at 144 Weeks

Triumeq Atripla
*CD4+ T-cells (also called T-cells) are white blood cells that help fight infections; table adapted from manufacturer data.
71% of patients who took Triumeq reached undetectable levels. 63% of patients who took Triumeq reached undetectable levels.
The average increase in CD4+ T-cell* count was 378 cells/mm3. The average increase in CD4+ T-cell* count was 332 cells/mm3.
4% of patients dropped out of the study due to side effects. 4% of patients dropped out of the study due to side effects.

The most common medium to severe side effects of Triumeq (in at least 2% of patients) when compared to Atripla treatment were found to be similar for each group.

Table 2: SINGLE Study: Triumeq Side Effects at 144 Weeks

Side Effect Triumeq Atripla
Trouble Sleeping 3% 3%
Headaches 2% 2%
Tiredness 2% 2%

Bottom Line

This is not all the information you need to know about Triumeq for safe use. Review the full information here, and speak to your health care provider if you have questions or concerns.

References

Read next

Does Triumeq cause erectile dysfunction?

Triumeq is unlikely to cause erectile dysfunction (ED), and ED is not listed as a side effect in the product information nor reported in post-marketing data – these are studies done after a drug has been approved. A review concluded that newer HIV combination treatments in use today have no clear-cut association with ED. Older HIV agents, such as zalcitabine (no longer in use) and enfuvirtide (rarely used) were known to cause ED. Using abacavir and raltegravir together had a weak association with ED, but no protease inhibitors appear to increase the risk. Triumeq contains three antivirals: abacavir and lamivudine and dolutegravir. Continue reading

Can Triumeq be crushed or split?

To ensure you receive the entire dose of Triumeq, the manufacturer recommends that ideally the tablet be swallowed whole. If you have trouble swallowing a whole tablet, crushing or splitting tablets may be an acceptable alternative, if approved by your healthcare provider. Do not chew, cut, or crush the Triumeq PD tablets. Continue reading

Triumeq vs Genvoya. How do they compare?

Both Triumeq and Genvoya are combination one-tablet-a-day medicines that are considered first-line treatments for HIV-1 by the HHS guidelines. Because Triumeq does not contain cobicistat, an antiviral booster, it is less likely to interact with other medications and may have fewer side effects than Genvoya. People taking Genvoya do not need to be tested for the HLA-B*5701 gene, because it does not contain abacavir. Continue reading

Related medical questions

Drug information

Related support groups